Synaptic Pharmaceutical Corporation

H. Lundbeck A/s

Carlos C Forray

Theresa A Branchek

Richard L Weinshank

Charles Gluchowski

Paul R Hartig

George Chiu

John M Wetzel

Jonathan A Bard

Kelli E Smith

David Linemeyer

Christophe P G Gerald

Christophe P Gerald

Douglas A Craig

Jonathon A Bard

This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Uses of galanin GALR2 receptors

Method of preparing GALR2 receptors composition

DNA encoding galanin GALR2 receptors

A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr; adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr; adrenergic receptor, a human &agr; adrenergic receptor, and a human histamine H receptor, and, binds to a human &agr; adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr; adrenergic receptor. Compounds meeting these criteria are provided.

Use of &agr;1C specific compounds to treat benign prostatic hyperplasia

Method of identifying compounds that bind galanin receptor (GALR2)

This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.

DNA encoding human alpha 1 adrenergic receptors and uses thereof

Methods of using DNA encoding human alpha 1 adrenergic receptors

This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors.

DNA encoding human .alpha. 1 adrenergic receptors and uses thereof

Use of alpha-1C specific compounds to treat benign prostatic hyperplasia

.alpha..sub.1C specific compounds to treat benign prostatic hyperplasia

This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising an isolated nucleic acid encoding a galanin receptor, cells comprising such vectors, antibodies directed to the galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding galanin receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid encoding a galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant galanin receptor, as well as methods of determining binding of compounds to the galanin receptor.

Method of identifying ligands which bind recombinant galanin receptor

DNA endoding human alpha 1 adrenergic receptors

A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.

Use of .alpha..sub.1c specific compounds to treat benign prostatic

This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor.

The present invention provides a method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the following structure: ##STR1## wherein each of the substiutents for the compound is as defined in the specification.

Growing community of inventors

Paramus, NJ, United States of America

Carlos C Forray